Initially described as an interferon (IFN)γ-inducing factor, interleukin (IL)-18 is indeed involved in Th1 and NK cell activation, but also in Th2, IL-17-producing γδ T cells and macrophage activation. IL-18, a member of the IL-1 family, is similar to IL-1β for being processed by caspase 1 to an 18 kDa-biologically active mature form. IL-18 binds to its specific receptor (IL-18Rα, also known as IL-1R7) forming a low affinity ligand chain. This is followed by recruitment of the IL-18Rβ chain. IL-18 then uses the same signaling pathway as IL-1 to activate NF-kB and induce inflammatory mediators such as adhesion molecules, chemokines and Fas ligand. IL-18 also binds to the circulating high affinity IL-18 binding protein (BP), such as only unbound free IL-18 is active. IL-18Rα may also bind IL-37, another member of the IL-1 family, but in association with the negative signaling chain termed IL-1R8, which transduces an anti-inflammatory signal. IL-18BP also binds IL-37 and this acts as a sink for the anti-inflammatory properties of IL-37. There is now ample evidence for a role of IL-18 in various infectious, metabolic or inflammatory diseases such as influenza virus infection, atheroma, myocardial infarction, chronic obstructive pulmonary disease, or Crohn's disease. However, IL-18 plays a very specific role in the pathogenesis of hemophagocytic syndromes (HS) also termed Macrophage Activation Syndrome. In children affected by NLRC4 gain-offunction mutations, IL-18 circulates in the range of tens of nanograms/mL. HS is treated with the IL-1 Receptor antagonist (anakinra) but also specifically with IL-18BP. Systemic juvenile idiopathic arthritis or adult-onset Still's disease are also characterized by high serum IL-18 concentrations and are treated by IL-18BP.
| INTRODUCTION
IL-18 was first identified as "IFNγ-inducing factor" isolated in the serum of mice after an intraperitoneal endotoxin, following pretreatment with Proprionibacterium acnes, which stimulates liver's Kupffer cells. 1 With purification from mouse livers and molecular cloning of "IFNγ-inducing factor" in 1995, the name was changed to IL-18 which unexpectedly, appears to be related to IL-1 family and particularly to IL-1β in several ways. 2, 3 Human IL-18 and IL-1β although sharing only 15% sequence homology, share a common β-pleated sheet structure. [3] [4] [5] IL-18 similarly to IL-1β is synthesized as an inactive precursor that lacks a signal peptide and needs caspase 1-mediated cleavage to become biologically active. Despite binding to different receptors, IL-1β and IL-18 use the same signaling pathways. However, apart from these important similarities, IL-18 and IL-1β appear to have a different biology. 4, 6, 7 This article is part of a series of reviews covering The IL-1 cytokine and receptor family appearing in Volume 281 of Immunological Reviews.
| IL-18BIOLOGY

| Celloriginandprocessing
IL-18 gene is located on chromosome 11 in humans and chromosome 9 in mice whose gene contains 7 exons with two distinct promoters on exon 1 and 2 including an interferon consensus sequence binding protein and a PU.1 binding sites. 5 In contrast to other cytokine genes, IL-18 gene has few RNA-destabilizing elements, resulting in an unusually stable cytokine expression. Transcription of IL-18 precursor can be induced after TLR binding of PAMPs and activation of the NF-κB pathway. IL-18 gene encodes for a 193 amino acids precursor, first synthesized as an inactive 24-kDa precursor with no signal peptide, which accumulates in cell cytoplasm. In contrast with IL-1β, the IL-18
precursor is constitutively present in blood monocytes, macrophages, dendritic cells from healthy subjects. 6, 8 Similarly to IL-1α and IL-33, the IL-18 precursor is constitutively expressed in endothelial cells, keratinocytes or intestinal epithelial cells throughout the gastrointestinal tract and remains in the intracellular compartment of mesenchymal cells.
Similarly to IL-1β, the IL-18 precursor is processed intracellularly by caspase 1 into its mature biologically molecule of 18 kDa. 
| IL-18receptorandsignalingpathways
IL-18 forms a signaling complex by binding to the IL-18 alpha chain (IL-18Rα), which is the ligand binding chain for mature IL-18; however, this binding is of low affinity ( Figure 1 ). 19 In cells that express the co-receptor, termed IL-18 receptor beta chain (IL-18Rβ), a high affinity complex is formed, which then signals. 20 The complex of IL-18 with the IL-18Rα and IL-18Rβ chains is similar to that formed by other members of the IL-1 family with the co-receptor, the IL-1R accessory chain IL-1RAcP (also termed IL-1R3). Although nearly all cells express the IL-1R1, not all cells express IL-1RAcP. 21 Similarly, most cells express the IL-18Rα but not all cells express the IL-18Rβ. IL-18Rβ is expressed on T-cells and dendritic cells but not commonly expressed in mesenchymal cells. Following the formation of the heterodimer, the Toll-IL-1 receptor (TIR) domains approximate and it appears that the cascade of sequential recruitment of MyD88, the four IRAKs and TRAF-6 followed by the degradation of IκB and release of NFκB are nearly identical as that for IL-1. 21 However, there are differences between IL-1 and IL-18 signaling. With few exceptions, IL-1α or IL-1β are active on cells in the low nanogram/mL range and often in the picogram/mL range. In contrast, IL-18 activation of cells expressing the two IL-18 receptor chains requires 10 to 20 ng/mL and sometime higher levels.
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In addition to NF-kB, the IL-18/IL-18Rα/IL-18Rβ complex has been shown to induce phosphorylation of STAT3 in an NK and hippocampal cell lines and the p38 MAP kinase pathway in neutrophils.
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| IL-37andIL-1R8
The tertiary structure of IL-18 is closely related to IL-37 and the intron-exon borders of the IL-18 and IL-37 genes suggest a close 
| ProinflammatorypropertiesofIL-18
Independently of IFNγ or other cytokines, IL-18 exhibits characteristics of other proinflammatory cytokines, such as increases in cell adhesion molecules, nitric oxide synthesis, and chemokine production. is not sufficiently high enough to neutralize IL-18 and therefore, the level of free IL-18 is higher than in healthy subjects. The same observation has been made in situations such as sepsis, sJIA and macrophage activation syndrome. 55, 56 A unique property of IL-18BP is that the molecule also binds the anti-inflammatory cytokine, IL-37. Thus, in any pathological condition, the outcome is the result of the concentrations of active IL-18, the surface level of IL-18Rα, the presence of IL-1R8 and the level of IL-18BP ( Figure 1 ). 26 Hence, the anti-inflammatory property of IL- 
| IL-18INPATHOLOGICALCONDITIONS
Several autoimmune diseases are associated with elevated production of IFNγ and IL-18. Diseases such as systemic lupus erythematosus, rheumatoid arthritis, Type-1 diabetes, Crohn's disease, psoriasis and graft vs host disease are thought to be mediated in part, by IL-18 and has been previously reviewed. [4] [5] [6] [7] In this review, we will discuss the role of IL-18 in the pathogenesis of inflammatory bowel diseases, metabolic syndrome and cardiovascular diseases, lung inflammatory diseases, sepsis, hemophagocytic syndromes and systemic juvenile idiopathic arthritis.
| IL-18ininflammatoryboweldiseases
Innate immunity and inflammasome activation, notably NLRP3, are implicated in the earlier phases of Crohn's disease. 61 The dysbiotic microbiota is transferrable to wildtype mice in which it suppresses NLRP6 activation, dampens IL-18 production, decreases antimicrobial peptide production, and increases the severity of DSS colitis. 83, 84 Interestingly, this phenotype can be reversed by IL-18 injection.
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The digestive tract is a complex organ since it tolerates millions of commensal bacteria yet the intestine rapidly recognizes pathogenic microorganisms and eliminates them. This is due to the different bar- In case commensal bacteria enter the mucosa (pink arrow), macrophages from the lamina propria secrete IL-18 which controls infection and IL-1β which has healing properties. In pathogenic conditions (B), the epithelial barrier is disrupted and bacteria enter massively in the lamina propria where they induce local macrophages to produce IL-18 which is detrimental (purple) and IL-1β (pink) which is protective. Disrupted IEC also release IL-1α which is highly proinflammatory in this setting (purple) and activates macrophages. This leads to chemokine secretion and leukocyte recruitment from the peripheral blood into the lamina propria. In the meantime, IL-18 inhibits mucus production by goblet cells and modify microbiota favoring dysbiosis Repair express the IL-18R. 87 In case of chronic inflammation with anatomical barrier rupture and dysbiosis on the contrary, IL-18 is detrimental.
NLRP3 and other inflammasomes may be activated in mononuclear cells from the lamina propria inducing large concentrations of pathogenic IL-18, leukocyte recruitment and severe inflammation. 88, 89 In this setting, IL-1α constitutively present in intestinal epithelial cells is released by injured cells and has an important pro-inflammatory role, whereas IL-1β secreted by mononuclear cells from the lamina propria has been shown to play a rather protective healing role. 90 Anti-TNFα and anti-IL-12/23 are efficient treatments in inflammatory bowel diseases, likely via the decrease in IFNγ. 91, 92 Since TNFα can induce IL-18, it is possible that part of the action of anti-TNFα may in fact be due to IL-18 inhibition.
| IL-18inmetabolicsyndromeanddiabetes type 2
The metabolic syndrome is characterized by central obesity, acquired insulin resistance, high blood triglycerides, low HDL, blood hyperten- is not unexpected. [96] [97] [98] In addition, a polymorphism of IL-18 gene associated with increased serum IL-18 levels has been linked to insulin resistance and metabolic syndrome. 99 The visceral rather than subcutaneous adipose tissue from obese individuals produces more IL-18 than lean controls, and serum IL-18 concentrations decreased after bariatric surgery. [100] [101] [102] Despite these data suggesting a link between high IL-18 concentrations and metabolic syndrome or type 2 diabetes, studies in mice reveal paradoxical observations. IL-18 or IL-18Rα-deficient mice, far from being protected from metabolic syndrome, appeared to become obese and develop insulin-resistance after 6 months of normal chow diet, due to both hyperphagia and decrease energy consumption. IFNγ concentrations in broncho-alveolar lavage fluids, whereas the same model in IL-13-deficient mice, the infiltrating eosinophils were less and airway hyperesponsiveness was reduced. 140 In summary, due to its Th-2 inducing functions, IL-18 may participate in airway inflammation and hyperresponsiveness in allergic asthma and may be an interesting therapeutic target in severe asthma resistant to steroids.
| Chronicobstructivepulmonarydisease
Chronic obstructive pulmonary diseases (COPD) include lung emphysema and chronic bronchitis, both characterized by chronic inflammation, alveolar destruction, airway remodeling and fibrosis. 141 The main causes of COPD are cigarette smoking (primary or second-hand) and air pollution. Cigarette smoke contain more than 4500 chemical products, oxidants and free-radicals that activate the innate immune system and induce lung inflammation. 142 IL-18 has been shown to be highly expressed in alveolar macrophages, CD8 T lymphocytes as well as bronchiolar and alveolar epithelial cells from patient lungs, whereas circulating 18Rα-expressing T cells were higher in COPD patients. [143] [144] [145] Serum IL-18 concentrations are increased in COPD and smokers when compared to non-smokers healthy controls, correlated positively with disease severity and negatively with the forced expiratory volume tests. 144 In mice, chronic exposure to cigarette smoke induces emphysema, small-airway remodeling and even pulmonary hypertension thus mimicking COPD. After 2-week smoke exposure in this model, IL-18 was increased in lung biopsies and the broncho-alveolar lavage fluid, especially in alveolar macrophages, associated with increased levels of caspases 1 and 11. In IL-18Rα KO mice, alveolar cell apoptosis, protease and chemokine production significantly decreased, reducing both inflammation and lung emphysema. 144 
| Acutelunginjury
NLRP3 is expressed in lung epithelial cells as well as in monocytes and macrophages and NLRP3 activation is protective in various models of lung infection, however, excessive NLRP3 stimulation has been demonstrated to be detrimental and may cause acute lung injury. 150 The most severe form of acute lung injury is represented by acute respiratory distress syndrome (ARDS) with a 40%-mortality. 151 IL-18
concentrations have been found elevated in the serum and lung of patients with ARDS (in the order of 600 pg/mL), and correlated with severity score and death. 152, 153 Among the most severe forms of ARDS are those induced by avian influenza virus. Seasonal influenzae RNA and M2 proteins are known to activate NLRP3 inflammasome in a protective way, since NLRP3-and caspase-1-deficient mice demonstrate more severe lung lesions as well as increased lethality. 154, 155 In this setting, although controversial, IL-18 but not IL-12, has been shown to be protective in the early defenses against influenza by inducing NK cell cytotoxicity and INFγ production. [156] [157] [158] On the contrary, avian influenzae H5N1 and H7N9 contain a PB1-F2 protein which maintain both inhibits IFNα production and activates NLRP3 in a strong and prolonged way. 159 This prolonged NLRP3 activation leads to excess IL-18 production and induces a very detrimental IFNγ-biased cytokine storm which appears to characterize ARDS pathogenesis. [160] [161] [162] Interestingly, this pathogenesis appears common to coronavirusinduced severe acute respiratory syndrome (SARS), another severe form of ARDS and possibly to the 1918 influenza virus. [163] [164] [165] This dual role of NLRP3 in influenza infection and potentially in ARDS has been recently demonstrated by temporal inhibition of NLRP3 using MCC950, a specific NLRP3 activation inhibitor.
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| IL-18insepsis
Sepsis is characterized by both excessive inflammation and immune suppression. 168 IL-18 and IL-18BP concentrations are elevated in the serum of pediatric and adult patients with sepsis, are free IL-18 remains higher than in healthy individuals or in non-septic patients. 43, 55 In postoperative sepsis patients, high IL-18 serum levels during the 2 first days represent an early predictive factor for a lethal outcome, possibly suggesting a role for IL-18 in the pathogenesis of sepsis. 169 Interestingly, caspase 1 KO mice are protected against LPS-induced septic shock, whereas IL-1β KO mice are not. 170 In agreement, anti-IL-18 monoclonal antibody treatment appears to be protective in two models of E. coli or Salmonella LPS-induced septic shock, decreasing neutrophils in the liver and lungs, and IFNγ, TNFα or chemokine serum concentrations. 170 Also, combined IL-1β and IL-18 inhibition has been shown to be protective in models induced by LPS injection or cecal ligation. 171 IL-18 appears to be especially important in mediating endotoxin-induced liver and lung injuries.
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The presence of free IL-18 in sepsis serum due to an imbalance of IL-18/IL-18BP ratio, lead to the use of IL-18BP in a murine model of cecal ligation. However, IL-18BP injection 8 hours after sepsis onset appeared slightly protective in the more severe forms, but not in those with a low predicted mortality rate. In contrast, after the administration of high doses of LPS, high concentrations of IL-18 and IFNγ are observed, which increased until death, associated with reduced antibacterial defenses. In the latter case, anti-IL-18 restores antibacterial defenses and is protective of a fatal outcome, whereas it decreased defenses in the former situation, suggesting an optimal range of IL-18 concentration is essential for host defenses. 175 These data may be in part explained by a positive loop of induction of caspase 1 mRNA transcription by IFNγ, leading to sustained IL-18 and IFNγ levels. 176 More recently, the role of IL-18 and its capacity to induce IL-17 in conjunction with IL-1 has been outlined in a model of neonatal sepsis. 43 Premature infants have elevated serum concentrations of IL-18 which increases in sepsis, associated with an inverse correlation with the gestational age. In a lethal model of neonatal sepsis, IL-18-deficient mice were protected whereas the administration of IL-18 increased lethality. In this model, ablation of the adaptive immune system afforded no protection, whereas treatment with anti-IL-17 was protective, due to the fact that IL-18 induced IL-17 secretion by γδ T cells from injured digestive tract or the lungs.
Interestingly, in this model IL-1R1-but not IL-1β-deficient mice were protected, suggesting a role for IL-1α which was found highly expressed in the gut of septic neonatal mice treated with IL-18. IL-17 is known to play a role in neutrophil-induced inflammation and IL-18 is known to increase PMN functions. 25, 177 Thus, despite a protective role of IL-18 and IL-17 in host defense against infection, their combined excessive actions during sepsis may become deleterious.
The duality of IL-18 in sepsis and possibly in other models of cytokine storm might be explained by different inflammasome and caspase involvement. Caspase 1-deficient mice which are resistant to endotoxic shock, are in fact deficient in both caspase 1 and caspase 11.
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Interestingly, NLRP3-deficient mice are not protected against sepsis, despite the fact that NLRP3 controls caspase 1 activation and both IL-1β and IL-18 secretion, suggesting that caspase 11, rather than caspase 1 may play an essential role in the protection of caspase 1/11-deficient mice toward sepsis. 178 Caspase 11 is mainly involved in a non-canonical inflammasome in mice. Caspase 11 oligomerizes with CARD to sensor intra-cytoplasmic LPS, usually due to high serum concentrations of LPS, and induces pyroptosis-mediated cell death. This mechanism dominates over that of canonical inflammasomes, which activate caspase1, such as NLRP3. 179 Excess of pyroptotic cell death may induce both strong IL-18 and DAMPS release inducing an "ecosanoid storm," shock and death. 
| IL-18inhemophagocyticsyndromes
Hemophagocytic syndromes or hemophaphagocytic lymphohistiocytosis (HLH) are characterized by the association of clinical and biological symptoms such as fever, hepatomegaly, splenomegaly, cytopenia, hyperferritininemia, hypertriglyceridemia, intravascular coagulation and could result in multivisceral deficiency. 180 The presence of hemophagocytosis in the bone marrow is not required for the diagnosis, but its presence in this clinical picture is highly suggestive of the disease. Noteworthy is the fact that hemophagocytosis may also be frequently observed in the bone marrow of sepsis patients.
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HLH can be divided in two presentations. The primary form usually occurs early in life and is due to recessive mutations affecting proteins involved in lymphocyte cytotoxicity, such as perforin, Munc 13D, syntaxin 11, Munc 18-2, rab27 or Lyst. 182 The other HLH syndrome, is also known as Secondary HLH or Macrophage Activation Syndrome, complicates infections, notably due to intracellular micro-organisms, lymphoma or rheumatic diseases, such as systemic lupus erythematosus or systemic juvenile idiopathic arthritis (sJIA) and its adult equivalent, adult-onset Still's disease (AOSD). 183 Animal models can mimick the two forms of HLH. Perforin-deficient mice infected with lymphocyte choriomeningitis virus (LCMV) was the first published model of primary HLH, followed by models using Munc 13D-or Rab27-deficient mice, or murine cytomegalovirus (MCMV) infection. [184] [185] [186] Another model mimicking secondary HLH is due to TLR-9 hyperstimulation by repeated CpG injections into wildtype mice. 187 More recently, other models of secondary HLH have been reported, such as LPS stimulation in mice overexpressing IL-6, EBV, Salmonella typhimurium or murine cytomegalovirus (MCMV) infection in humanized or wildtype mice. 188, 189 In humans as well as in all these animal models, excess circulating inflammatory cytokines with a rather Th1 profile, designed as a "cytokine storm," is the primary event. 184, 187, 190 Among them, IFNγ seems to play the important pathogenic role, since inhibition of IFNγ appears protective in most murine models. 184, 187, 191 It is not completely clear, however, since some models depend also on TNFα or other cytokines. 189, 192, 193 The role of IL-18 in HLH is likely due to its capacity to induce IFNγ and pro-inflammatory cytokines. Several reports have found elevated IL-18 concentrations in the serum of patients with both primary and secondary HLH as well as in animal models and IL-18 correlated with the biological criteria and evolution of the disease. 56, 184, 187, 191, 194, 195 Usually, the concentrations of IL-18 range from 0.6 to 3 ng/mL in HLH patients. There is the exception in two conditions, in which IL-18 concentrations are higher than 5 ng/mL, namely XLP type 2 due to XIAP mutations and sJIA/AOSD. 195, 196 In both situations, IL-18 concentrations do not return to normal levels even after recovery of the HLH. Such elevated concentrations are unusual for an inflammatory cytokine and question its significance, especially since in the majority of these studies, the distinction between total IL-18 and free IL-18
was not made. In a previous study of Secondary HLH complicating lymphoma, infections and AOSD, we observed an increase in free IL-18, IL-18BP concentrations being similar to those in control patients without HLH, perhaps suggesting a relative resistance of IL-18BP synthesis to IFNγ which was elevated in these patients. 56 trations. 198 Noteworthy is the fact that in this animal model, no anticytokine strategy has been shown to increase survival probably due to the fact that concentrations of IFNγ and TNFα are found, respectively, 10-fold and 5-fold higher than in the LCMV-infected perforin-deficient model. 184, 186, 199 However even in the perforin KO-LCMV model, anti-IL-18 treatment did not significantly influence animal survival. 184 Despite disappointing animal data, the role of IL-18 in HLH is valide. In 2014, two independent groups reported on two pediatric patients with severe refractory HLH and digestive tract lesions without mutations affecting cytotoxicity, but bearing gain-of-function mutations of the NLRC4 inflammasome. 66, 200 Ex vivo experiments showed that these mutations induced very high concentrations of IL-18 (10 ng/mL), whereas IL-1β was modestly affected. 203 Systemic JIA is clinically characterized by high spiking fever, cutaneous rash, hepato/splenomegaly, serositis, whereas arthritis the main symptom in JIA, could be absent at least at the disease onset. Biologically, sJIA is characterized by severe generalized inflammation, neutrophilia, thrombocytosis, and hyperferritinemia. 204 An unusually frequent complication of sJIA is macrophage activation syndrome (MAS), a form of secondary HLH, which occurs in 15% of the patients, whereas hemophagocytosis ("occult MAS") may be present in the bone marrow of almost 50% of the patients with active sJIA, suggesting a special pathogenic link between these 2 diseases. 205 Initial gene expression profile study discovered an IL-1 signature in sJIA, and other studies have found upregulation of a cluster of genes involved in innate immunity and IL-1R/TLR signaling. 206, 207 Nevertheless, treatments with anakinra (IL-1 Receptor antagonist) or canakinumab (anti-IL-1β monoclonal antibody) are effective in nearly 50% of the patients. Another group of patients, however, with a greater number of involved joints and lower neutrophil count may not or incompletely respond to anakinra, developing persistent synovitis. 208 It is also possible to distinguish two different subgroups of sJIA patients depending on their serum cytokine profile, the group with more severe arthritis having higher concentrations of IL-6. 209 Indeed IL-6 is markedly elevated in sJIA patients and correlates with the severity of joint involvement. 210 Inhibition of IL-6 using the IL-6 receptor blocking antibody tocilizumab may be an effective treatment in sJIA patients not responding to IL-1β blockade.
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IL-18 has been found highly elevated in the serum of active sJIA in numerous studies. [212] [213] [214] In addition, the links of MAS with primary HLH leads to the search for a common pathogenic pathway. NK cell cytotoxicity was reported to be abnormal in patients with active sJIA with or without MAS, consisting in decreased circulating NK numbers, perforin expression and cytotoxicity. [223] [224] [225] In addition, whole exome sequencing reported that heterozygous mutations affecting Munc13.4, Munc 18.2 or Lyst were present in 35% of sJIA patients with MAS, but only in 14% of patients with sJIA without MAS. 226 Furthermore, in animal models of sJIA consisting in complete Freund's adjuvant administration in IFNγ KO mice or in LPS-stimulated mice overexpressing IL-6, NK cell lymphopenia as well as decreased cytotoxicity was observed. 220, 227 A more recent study, however, showed that after normalization of NK percentage, no cytotoxicity deficiency was observed in sJIA patients and only minor NK abnormalities such as increased surface NKp44 expression and decreased granzyme K expression were present. 
